Metabolic Surgery for Obese Type 2 Diabetes: Korean Multicenter Cohort Study - Scorecard - MDSpire

Metabolic Surgery for Obese Type 2 Diabetes: Korean Multicenter Cohort Study

  • By

  • Young Suk Park

  • Soo Min Ahn

  • Sang Hyun Kim

  • Sung Il Choi

  • Kyung Won Seo

  • Han Hong Lee

  • Youngsung Suh

  • Ji Yeon Park

  • Sang Eok Lee

  • Sungsoo Park

  • Dong Jin Kim

  • In Cho

  • Yoo Min Kim

  • Songchang Shi

  • Tae Jung Oh

  • Yun-Suhk Suh

  • Ki Hyun Kim

  • Seungwan Ryu

  • Mi Kyung Kim

  • Do Joong Park

  • Seong-Ho Kong

  • Young Min Cho

  • In Gyu Kwon

  • Jong Suk Park

  • Minyoung Lee

  • Hyuk-Joon Lee

  • November 13, 2025

  • 0 min

Share

Clinical Scorecard: Surgical Interventions for Type 2 Diabetes in Obese Patients: A Multicenter Study from Korea

At a Glance

CategoryDetail
ConditionType 2 diabetes mellitus (T2DM) in obese patients
Key MechanismsIncreased GLP-1 secretion enhancing insulin secretion and suppressing glucagon; changes in gut microbiota and bile acid metabolism improving insulin sensitivity
Target PopulationObese adults (BMI ≥ 30 kg/m²) with T2DM, specifically Korean/East Asian patients
Care SettingMetabolic/bariatric surgery performed by board-certified surgeons in specialized centers

Key Highlights

  • Metabolic/bariatric surgery (MBS) is effective for weight loss and T2DM remission, with SG and RYGB as common procedures.
  • RYGB generally yields greater weight loss and glycemic control but with potentially higher complexity and complications compared to SG.
  • East Asian populations develop T2DM at lower BMI thresholds, necessitating population-specific evidence for surgical decision-making.

Guideline-Based Recommendations

Diagnosis

  • T2DM diagnosis confirmed by HbA1c and fasting blood glucose levels.
  • Obesity defined as BMI ≥ 30 kg/m², with consideration of lower BMI thresholds in Asian populations.

Management

  • Consider metabolic/bariatric surgery for T2DM patients with BMI ≥ 30 kg/m², especially in Asian populations.
  • Choice between SG and RYGB should be individualized based on patient risk profile and expected outcomes.
  • Concomitant hiatal hernia repair performed when present during surgery.

Monitoring & Follow-up

  • Postoperative monitoring of T2DM remission defined by medication cessation and HbA1c < 6.0% or FBG < 100 mg/dL at 1 and 2 years.
  • Assessment of weight loss, hypertension, dyslipidemia, and postoperative complications per American Society of Metabolic and Bariatric Surgery criteria.

Risks

  • Potential surgical complications vary between SG and RYGB; SG has fewer complications but possibly less glycemic efficacy.
  • Consideration of gastric cancer risk in Korean patients influencing surgical approach (e.g., resectional gastric bypass).

Patient & Prescribing Data

Korean adults with obesity and T2DM undergoing SG or RYGB between 2019 and 2021

Both SG and RYGB lead to T2DM remission and weight loss; RYGB may offer superior glycemic outcomes but with increased complexity; population-specific data supports tailored surgical decisions.

Clinical Best Practices

  • Use IPTW with propensity scores to adjust for baseline differences in comparative studies of SG vs RYGB.
  • Perform surgeries by accredited metabolic and bariatric surgeons to ensure standardized technique and outcomes.
  • Define T2DM remission rigorously as cessation of diabetes medications with HbA1c < 6.0% or FBG < 100 mg/dL.
  • Consider ethnic and phenotypic differences in T2DM and obesity when applying international guidelines to East Asian patients.

References

Original Source(s)

Related Content